14:00 – 14:30  Report on Subgroup Activities

David Leiby

- Parasite Survey accepted as an International Forum
  - thanks to Henk Reesink and Desanka Heidsieck
  - handled similarly to recent NAT survey
  - guest editorship with inclusion of collaborators
- Completion and distribution of survey
  - given nature of parasitic infections sought broader distribution range than normal IF normal
  - additional contacts provided by ISBT members
  - will seek additional coverage as needed
  - English and Spanish versions

- Summary of survey results to date
  - historical accounting of TTP
  - worldwide mitigation approaches
    - deferrals
    - testing
    - pathogen reduction
    - etc.
Survey Distribution
Surveys Returned to Date
14:30 – 14:50 Update on *Babesia microti* mitigation efforts the United States

*David Leiby et al.*

- **current status of TTB in U.S.**
  - 162+ cases of TTB (Herwaldt et al., 2011)
    - 159 cases attributable to *B. microti*
    - 3 cases attributable to *B. duncani*
  - babesiosis now nationally notifiable via CDC
  - deferral for “History of Babesiosis”
    - largely ineffective
  - absence of blood screening assay
  - BPAC supports concept of regionalized screening
  - several investigations currently under IND
Current Studies Under IND

- Rhode Island Blood Center/Imugen
  - selective testing
  - initial data published
- American Red Cross/Imugen
  - retrospective and prospective testing
- BSRI/Immunetics
  - assay development
  - clinical trials
- Other studies involving Imugen
Presentation: *Babesia* in Australia – implications for blood safety

*Clive Seed*

- first case of human babesiosis described in Australia
- etiologic agent – *Babesia microti*
  - confirmed by molecular methods
- *Ixodes* vector present in Australia
  - specific vector not identified in this case
- limited current impact in Australia
- incomplete understanding of distribution of *Babesia* spp. worldwide
Presentation: Efficacy of Mirasol treatment of whole blood spiked with *Plasmodium falciparum* with both molecular and functional endpoints

**J.P. Allain/Mira El Chaar**

- efficacy of pathogen reduction demonstrated
- examined by molecular methods and parasite viability
  - not readily comparable
- discussed issues of experimental vs. “real” infection levels
15:30 – 16:00

Report on Malaria Risk Project (jointly with Subgroup on Epidemiology and Surveillance)

*Sheila O’Brien*

- summary provided by Sheila in Subgroup on Epidemiology and Surveillance report